Talphera Inc (TLPH)

Currency in USD
0.7852
+0.0462(+6.25%)
Closed·
0.8472+0.0620(+7.90%)
·
Unusual Post-Market activity
TLPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.71800.8400
52 wk Range
0.68661.5700
Key Statistics
Prev. Close
0.7852
Open
0.73
Day's Range
0.718-0.84
52 wk Range
0.6866-1.57
Volume
357.32K
Average Volume (3m)
143.74K
1-Year Change
-41.403%
Book Value / Share
0.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.1250
Upside
+297.99%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Talphera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.1250
(+297.99% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy3.00+282.07%-Maintain13-08-2026
H.C. Wainwright
Buy---New Coverage05-06-2026
WestPark Capital
Buy---New Coverage30-04-2026

Talphera Inc Earnings Call Summary for Q3/2026

  • Talphera posted Q3 2026 EPS of -$0.05, beating consensus of -$0.07 by 28.57%; shares surged 10.35% after-hours to $1.1421.
  • NEPHRO-CRRT study enrollment exceeded 75% of target; company requested FDA Sprint Meeting for potential early closure with response expected by year-end.
  • Management projects $14.2M cash plus ~$16M conditional financing will fund operations through potential 2027 PMA approval for Niyad anticoagulant.
  • Peak annual U.S. sales estimate for Niyad in CRRT raised to over $200M; investor event planned for Q1 2027 to detail commercial opportunity.
  • Operating expenses rose 15.2% YoY to $3.8M for development and pre-launch activities; top-line data expected 4-6 weeks post-enrollment closure.
Last Updated: 13-11-2026, 03:48 am
Read Full Transcript

Earnings

Latest Release
12-11-2026
EPS / Forecast
-0.05 / -0.07
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TLPH Income Statement

Compare TLPH to Peers and Sector

Metrics to compare
TLPH
Peers
Sector
Relationship
P/E Ratio
−2.8x−1.3x−0.2x
PEG Ratio
−0.06−0.030.00
Price/Book
3.8x1.8x2.6x
Price / LTM Sales
-8.9x2.6x
Upside (Analyst Target)
298.0%124.6%77.0%
Fair Value Upside
Unlock−8.1%13.7%Unlock

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Employees
12

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.66M3.20%1.30M
Other Institutional Investors
43.32M83.46%34.02M
Public Companies & Retail Investors
6.92M13.34%5.44M
Total
51.91M100.00%40.76M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
CorMedix Inc.17.51%90,90,9097,138
AIGH Investment Partners8.98%46,61,5023,660

FAQ

What Is the Talphera (TLPH) Share Price Today?

The Talphera share price today is 0.7852.

What is the current Talphera (TLPH) share price and day range?

As of 22-11-2026, the Talphera share price is 0.7852, with a previous close of 0.7852. The share price has ranged from 0.7180 to 0.8400 today, while the 52-week range spans from 0.6866 to 1.5700.

What Is the Talphera Market Cap?

As of today, Talphera market cap is 40.8000M.

What Is the Talphera (TLPH) Share Price Target?

The average 12-month share price target for Talphera is 3.1250, with a high estimate of 3.5 and a low estimate of 3. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +297.99% Upside potential.

What Is Talphera's Earnings Per Share (TTM)?

The Talphera EPS (TTM) is -0.20.

When Is the Next Talphera Earnings Date?

Talphera will release its next earnings report on 11-03-2027.

From a Technical Analysis Perspective, Is TLPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Talphera Trade On?

Talphera is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Talphera?

The stock symbol for Talphera is "TLPH."

How Many Times Has Talphera Stock Split?

Talphera has split 1 times.

How Many Employees Does Talphera Have?

Talphera has 12 employees.

What Is the TLPH Premarket Price?

TLPH's last pre-market stock price is 0.7280. The pre-market share volume is 15,310.0000, and the stock has changed by -0.0110, or -1.4900%.

What Is the TLPH After Hours Price?

TLPH's last after hours stock price is 0.8472, the stock has changed by 0.0620, or 7.9000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.